Hemophilia Gene Therapy Pipeline — PatSnap Eureka
Hemophilia A & B Gene Therapy: AAV Factor Replacement Pipeline
From B-domain deleted FVIII constructs to gain-of-function FIX variants, the hemophilia gene therapy landscape spans Phase 3 approvals to emerging non-viral platforms. Explore the IP signals, clinical programs, and assignee landscape powering this field.
F8 and F9: The Central Molecular Targets in Hemophilia Gene Therapy
Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency) are X-linked inherited bleeding disorders representing among the most clinically and commercially significant targets in gene therapy for rare diseases. Retrieved results uniformly identify the F8 gene (encoding coagulation Factor VIII, FVIII; UniProt P00451) and the F9 gene (encoding coagulation Factor IX, FIX; UniProt P00740) as the primary molecular targets.
A critical engineering constraint highlighted across multiple retrieved patents is the size of the FVIII coding sequence. The full-length wild-type FVIII polypeptide spans 2,351 amino acids — five times larger than wild-type FIX (461 amino acids) — with a coding sequence of approximately 7,053 base pairs that exceeds the packaging capacity of conventional AAV vectors. This drives the field toward B-domain deleted (BDD) constructs and codon optimization strategies.
Elevating clotting factor activity to as little as 1% above normal is sufficient to significantly reduce spontaneous bleeding events and long-term joint pathology. The liver is identified across retrieved results as the primary physiological site of FIX and FVIII synthesis and the preferred target organ for gene delivery, both for efficient entry of secreted factors into circulation and for induction of regulatory T cell (Treg)-mediated immune tolerance.
Secondary challenges include inhibitor antibody formation: 15–30% of individuals receiving FVIII replacement therapy develop neutralizing anti-FVIII antibodies, and approximately 10% of hemophilia B patients similarly develop anti-FIX inhibitors — complicating both protein replacement and gene therapy approaches. For a broader overview of the IP analytics tools used to map this landscape, see PatSnap's patent analytics platform.
Six Distinct Approaches Across the Hemophilia Gene Therapy Landscape
From AAV-delivered transgenes to non-viral platforms and gene editing, the pipeline spans multiple technology generations and development stages.
AAV Liver-Directed Gene Therapy (FVIII)
The dominant modality in retrieved results: recombinant AAV delivery of engineered FVIII transgenes to hepatocytes via AAV5, AAV6, AAV8, and chimeric capsids. Core strategy relies on B-domain deletion, codon optimization, and liver-specific regulatory elements. Valoctocogene roxaparvovec (BioMarin) has received European Commission approval per retrieved patent text, with 134 patients enrolled in Phase 3.
Phase 3 / EC ApprovedAAV Liver-Directed Gene Therapy (FIX)
A well-established paradigm that preceded hemophilia A efforts. Codon-optimized FIX transgenes delivered via liver-directed AAV, including gain-of-function FIX-Padua (Ile338Leu) variants enabling dose reduction. Regeneron's approach targets genomic integration at the albumin (ALB) locus for cell-division-stable expression — distinct from episomal AAV approaches.
Phase 2/3 AdvancedCodon Optimization & FVIII Variant Engineering
Systematic codon alteration to maximize mammalian cell expression. Strategies include CpG dinucleotide elimination (reducing innate immune activation), amino acid substitutions to improve secretion (e.g., F328S), and heterologous signal peptides to enhance ER entry. Specific constructs CS04-FL-NA, CS01-FL-NA, and hFVIII-BDD are recurrently cited across Takeda, Baxalta, and Spark Therapeutics patents.
Preclinical → ClinicalChimeric Protein & Extended Half-Life Factor Replacement
FVIII/FIX polypeptides fused to Fc domains, von Willebrand factor (VWF) D' and D3 fragments, and/or XTEN polypeptide sequences to extend half-life and reduce dosing frequency. Bioverativ/Biogen patents describe FVIII-Fc-XTEN-VWF fusion constructs combining multiple half-life extension strategies. rFVIIIFc (efmoroctocog alfa) referenced as approved or advanced-stage.
Clinical / ApprovedNon-Viral & Alternative Delivery Platforms
Generation Bio Co. describes closed-end DNA (ceDNA) vectors — non-viral, capsid-free, linear DNA constructs flanked by inverted terminal repeats — for FVIII expression. Explicitly addresses AAV limitations: pre-existing immunity in 25–40% of patients, inability to redose, and uncontrollable dose levels. Genzyme (Sanofi) describes lipid nanoparticle (LNP) delivery targeting hematopoietic stem cells (HSC) as an emerging non-AAV gene delivery approach.
Preclinical / EarlyGene Editing / F8 Mutation Repair
AAV vectors delivering donor templates for F8 gene repair, combined with immune tolerance induction to the subsequently expressed FVIII protein. Records from U.S. Government, Regents of the University of California, and Haplomics, Inc. describe this dual-mechanism approach addressing both the genetic deficit and inhibitor antibody barriers simultaneously. Distinct from transgene addition.
Early PreclinicalPipeline Signals: Enrollment, Modality Distribution & Assignee Activity
Key quantitative signals extracted from patent and literature records retrieved via PatSnap Eureka. All values are sourced directly from retrieved records.
Hemophilia A Clinical Program Enrollment
Patient enrollment across three active AAV gene therapy programs as reported in a 2022 University Medical Centre Utrecht paper. Valoctocogene roxaparvovec leads with 134 patients in Phase 3.
Pipeline Modality by Development Stage
Distribution of six hemophilia gene therapy modalities across development stages, from early preclinical to approved, based on patent and literature signals retrieved via PatSnap Eureka.
Top Assignees by Jurisdictional Filing Breadth
Relative IP filing activity of key assignees in the hemophilia gene therapy space, measured by jurisdictional breadth across retrieved patent records from PatSnap Eureka. Takeda/Baxalta leads the dataset.
Key Targets, Variants & Regulatory Elements Across Retrieved Records
Every target and strategy below is directly sourced from retrieved patent and literature records via PatSnap Eureka.
What the IP Landscape Signals for R&D Strategy
Key strategic takeaways derived exclusively from retrieved patent and literature records. Validated by PatSnap Eureka data.
Crowded IP Space: AAV/FVIII Codon Optimization
Codon optimization and BDD-FVIII engineering represent a crowded IP space dominated by Takeda/Baxalta, Spark Therapeutics, BioMarin, and UNC Chapel Hill, with overlapping claims across multiple jurisdictions. New entrants pursuing AAV/FVIII gene therapy will face significant freedom-to-operate challenges and should evaluate differentiation through novel capsids, novel regulatory elements, or non-AAV platforms.
Durability: The Central Unresolved Clinical Issue
Retrieved academic literature explicitly frames long-term follow-up data as the key uncertainty in hemophilia A gene therapy. Retrieved BioMarin IP addresses the adolescent patient population where episomal AAV vector genome dilution during liver growth is expected to limit durability — indicating the field will need genomic integration or redosing solutions to achieve lifetime treatment.
High-Value Whitespace: Anti-AAV Seropositivity
Pre-existing anti-AAV immunity (25–40% of patients excluded) represents a substantial unmet need directly addressed by only one retrieved assignee (BioMarin). Non-viral delivery platforms (ceDNA, LNP-HSC) are positioned by their filings explicitly to capture this excluded population — this is a high-value IP whitespace with limited competition in retrieved records.
Hemophilia B: Differentiated Opportunity in FIX Variants
The hemophilia B space contains a differentiated opportunity in gain-of-function FIX variants (FIX-Padua, FIX-Triple). Retrieved Stanford patent signals that combining improved hepatotropic capsids with high-potency FIX variants can substantially lower therapeutic vector dose, with favorable safety, manufacturing cost, and dose-titration implications.
From First Human Trials to Phase 3: The Clinical Translation Trajectory
Retrieved results contain multiple signals of clinical translation, primarily for hemophilia A AAV programs. Valoctocogene roxaparvovec (BioMarin) — referenced as receiving European Commission approval in retrieved patent text — showed "sustained transgene expression sufficient for hemostasis" with participants experiencing "significantly lower rates of bleeding compared with baseline on FVIII prophylaxis" (citing Rangarajan et al., N Engl J Med 2020).
The Takeda/Baxalta CS04 construct via rAAV8 has generated IND-enabling or early clinical data: retrieved patents (US jurisdiction, 2024) reference Factor VIII activity over time in the blood of four hemophilia A patients, along with TNFα and IL-6 cytokine monitoring in peripheral blood. Biodistribution data from this construct shows delivery to liver, lymph node, skeletal muscle, heart, kidney, spleen, lung, testis, and brain following systemic administration.
For hemophilia B, retrieved results from The Children's Hospital of Philadelphia reference the first AAV2-mediated FIX gene transfer to human liver (Manno et al., 2006) as a historical milestone. Academic literature also references a successful Spark Therapeutics FIX Padua-based trial reported at the World Federation of Hemophilia Congress 2016. For those seeking life sciences IP analytics tools to track these programs, PatSnap's life sciences platform provides structured pipeline intelligence.
Important limitation: Retrieved results contain no specific signals related to fitusiran clinical data. Fitusiran (an RNA interference-based antithrombin inhibitor) is not represented by records in this dataset. Any strategic analysis requiring coverage of antithrombin inhibition (fitusiran/Alhemo), anti-TFPI approaches (marstacimab), or emicizumab (bispecific antibody) will require targeted additional searches via PatSnap Analytics.
Hemophilia Gene Therapy Pipeline — Key Questions Answered
The F8 gene (encoding coagulation Factor VIII, FVIII) and the F9 gene (encoding coagulation Factor IX, FIX) are the primary molecular targets for hemophilia A and B gene therapy, respectively. Hemophilia A is the most common inherited bleeding disorder, occurring in approximately 1 in 5,000 live male births in the United States, with hemophilia A being approximately four times more prevalent than hemophilia B.
The full-length wild-type FVIII polypeptide (2,351 amino acids) is five times larger than wild-type FIX (461 amino acids), and its coding sequence of approximately 7,053 base pairs exceeds the packaging capacity of conventional AAV vectors. This drives adoption of B-domain deleted (BDD) FVIII constructs and codon optimization strategies.
A 2022 paper from University Medical Centre Utrecht identifies three active clinical programs: valoctocogene roxaparvovec (AAV5-hFVIII-SQ; BioMarin) with 134 patients enrolled in phase 3 and European Commission approval referenced; SPK-8011 (Spark Therapeutics) with 18 patients; and giroctocogene fitelparvovec (Pfizer/Sangamo) with 11 patients across dose cohorts.
B-domain deletion enables the FVIII coding sequence to fit within AAV packaging constraints. A 14-amino acid SQ linker replaces the deleted region, resulting in approximately a 17-fold increase in mRNA levels relative to full-length FVIII. The BDD-FVIII (hFVIII-SQ) construct is the standard transgene payload used across most clinical programs.
Pre-existing anti-AAV antibodies exclude approximately 25–40% of patients from first-generation AAV gene therapies. BioMarin's 2024 WO patent specifically covers methods for treating AAV-seropositive patients and enabling re-dosing, signaling recognition that this represents a substantial unmet need and commercially strategic IP whitespace.
Generation Bio Co. describes closed-end DNA (ceDNA) vectors — non-viral, capsid-free, linear DNA constructs — for FVIII expression, explicitly highlighting AAV limitations including pre-existing immunity in 25–40% of patients, inability to redose, and uncontrollable dose levels. Genzyme (Sanofi) describes lipid nanoparticle (LNP) delivery targeting hematopoietic stem cells (HSC) as another emerging non-AAV platform.
Still have questions about the hemophilia gene therapy pipeline? Let PatSnap Eureka search the patent literature for you.
Ask Eureka AI About Hemophilia Gene TherapyAccelerate Your Hemophilia Gene Therapy R&D with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search FVIII, FIX, AAV capsid, and non-viral delivery patents in seconds — with AI-synthesized insights across the full pipeline.
References
- A Cure For Hemophilia: the Promise Becomes a Reality — Anonymous/Review, 2016 [Paper]
- Gene Therapy for Hemophilia A: How Long Will It Last? — University Medical Centre Utrecht (Van Creveldkliniek), 2022 [Paper]
- Optimized human coagulation Factor VIII gene expression cassette and uses thereof — The University of North Carolina at Chapel Hill, 2020, AU [Patent]
- Chimeric factor VIII polypeptides and uses thereof — Biogen MA Inc., 2016, AU [Patent]
- Factor VIII (FVIII) Gene Therapy — Spark Therapeutics, Inc., 2024, JP [Patent]
- Methods of treating Anti-AAV seropositive hemophilia patients — BioMarin Pharmaceutical Inc., 2024, WO [Patent]
- Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression — Takeda Pharmaceutical Company Limited, 2024, US [Patent]
- Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A — Takeda Pharmaceutical Company Limited, 2018, SG [Patent]
- Vector for liver-directed gene therapy of hemophilia and methods and use thereof — Vrije Universiteit Brussel, 2019, US [Patent]
- Gene therapy for hemophilia B with a chimeric AAV capsid vector encoding modified Factor IX polypeptides — Board of Trustees of the Leland Stanford Junior University, 2021, WO [Patent]
- Compositions and methods for expressing Factor IX for hemophilia B therapy — Regeneron Pharmaceuticals, Inc., 2024, JP [Patent]
- Non-viral DNA vectors and uses thereof for expressing FVIII therapeutics — Generation Bio Co., 2023, CN [Patent]
- Manno et al. — First AAV2-mediated FIX gene transfer to human liver — Nature Medicine, 2006 [Paper]
- Rangarajan et al. — Valoctocogene roxaparvovec Phase 1/2 results — New England Journal of Medicine, 2020 [Paper]
- World Federation of Hemophilia — Spark Therapeutics FIX Padua trial results — WFH Congress, 2016 [Conference]
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.